Comparative Pharmacology
Head-to-head clinical analysis: ISOPAQUE 440 versus ORAGRAFIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPAQUE 440 versus ORAGRAFIN SODIUM.
ISOPAQUE 440 vs ORAGRAFIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays by increasing the iodine content in tissues, providing enhanced visualization of vasculature and organs during imaging procedures.
Oragrafin Sodium is an oral cholecystographic contrast agent containing sodium ipodate. It is absorbed orally, excreted by the liver into bile, and concentrates in the gallbladder, allowing radiographic visualization. The iodine atoms in the molecule absorb X-rays, providing contrast. It also inhibits thyroid hormone synthesis by blocking iodine organification and may be used in amiodarone-induced thyrotoxicosis.
Intravenous: 50-100 mL (22.05-44.1 g iodine) as a single dose for CT imaging; intra-arterial: 5-80 mL (2.2-35.28 g iodine) depending on procedure; dose is based on imaging requirements and patient weight.
Oral: 50-60 mL of a 10% solution (5-6 g sodium iopodate) as a single dose 10-12 hours before cholecystography. Repeat if needed: 50 mL (5 g) the next evening. Intravenous: Not applicable (oral agent).
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 to 2 hours in patients with normal renal function. May be prolonged in renal impairment, correlating with creatinine clearance; dose adjustment not typically required for diagnostic procedures.
Terminal elimination half-life is approximately 60-90 minutes in patients with normal renal function (creatinine clearance > 90 mL/min), reflecting rapid renal clearance of this water-soluble contrast agent.
Primarily renal excretion via glomerular filtration. Approximately 95% of the administered dose is excreted unchanged in the urine within 24 hours. Less than 5% is eliminated via biliary/fecal routes.
Primarily renal (hepatic/biliary/fecal: minimal). Approximately 80-90% of the absorbed dose is excreted unchanged in urine via glomerular filtration; <10% eliminated in feces via biliary excretion.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent